Rosetta Genomics Performance
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Rosetta Genomics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Rosetta Genomics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Rosetta Genomics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Fifty Two Week Low | 0.4201 | |
| Fifty Two Week High | 0.4390 |
Rosetta |
Rosetta Genomics Relative Risk vs. Return Landscape
If you would invest (100.00) in Rosetta Genomics on January 25, 2024 and sell it today you would earn a total of 100.00 from holding Rosetta Genomics or generate -100.0% return on investment over 90 days. Rosetta Genomics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Rosetta, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rosetta Genomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rosetta Genomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rosetta Genomics, and traders can use it to determine the average amount a Rosetta Genomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ROSG |
Based on monthly moving average Rosetta Genomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rosetta Genomics by adding Rosetta Genomics to a well-diversified portfolio.
Rosetta Genomics Fundamentals Growth
Rosetta Stock prices reflect investors' perceptions of the future prospects and financial health of Rosetta Genomics, and Rosetta Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rosetta Stock performance.
| Return On Equity | -137.95 | |||
| Return On Asset | -60.19 | |||
| Operating Margin | (370.55) % | |||
| Current Valuation | 2.09 M | |||
| Shares Outstanding | 5.93 M | |||
| Price To Earning | (0.09) X | |||
| Price To Book | 1.01 X | |||
| Price To Sales | 0.72 X | |||
| Revenue | 2.86 M | |||
| EBITDA | (10.35 M) | |||
| Cash And Equivalents | 1.32 M | |||
| Cash Per Share | 0.51 X | |||
| Total Debt | 2.45 M | |||
| Debt To Equity | 222.80 % | |||
| Book Value Per Share | 0.43 X | |||
| Cash Flow From Operations | (11.68 M) | |||
| Earnings Per Share | (6.41) X | |||
| Total Asset | 22.42 M | |||
| Retained Earnings | (140.27 M) | |||
| Current Asset | 19.37 M | |||
| Current Liabilities | 2.8 M | |||
Things to note about Rosetta Genomics performance evaluation
Checking the ongoing alerts about Rosetta Genomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rosetta Genomics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rosetta Genomics is not yet fully synchronised with the market data | |
| Rosetta Genomics has some characteristics of a very speculative penny stock | |
| Rosetta Genomics has a very high chance of going through financial distress in the upcoming years | |
| Rosetta Genomics has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 2.86 M. Net Loss for the year was (9.48 M) with profit before overhead, payroll, taxes, and interest of 498 K. | |
| Rosetta Genomics currently holds about 1.32 M in cash with (11.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51. |
- Analyzing Rosetta Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rosetta Genomics' stock is overvalued or undervalued compared to its peers.
- Examining Rosetta Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rosetta Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rosetta Genomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rosetta Genomics' stock. These opinions can provide insight into Rosetta Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Rosetta Stock
If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |